行情

CAPR

CAPR

Capricor
NASDAQ

实时行情|Nasdaq Last Sale

1.820
+0.070
+4.00%
盘后: 1.930 +0.11 +6.04% 16:39 11/15 EST
开盘
1.760
昨收
1.750
最高
1.820
最低
1.760
成交量
2.17万
成交额
--
52周最高
9.50
52周最低
1.709
市值
772.81万
市盈率(TTM)
-0.4842
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CAPR 新闻

  • 马斯克:NASA付给波音载人航天费用太高 这不公平
  • 新浪科技.5小时前
  • 波音737客机又出事!飞行途中出现故障 紧急迫降
  • 海外网.6小时前
  • 约500万美国人有睡眠问题 手机可能是罪魁祸首
  • 新华国际.6小时前
  • 世界首富易主!比尔·盖茨反超亚马逊CEO贝佐斯登顶
  • 中国新闻网.6小时前

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

CAPR 简况

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.
展开

Webull提供Capricor Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。